I'll research CI (The Cigna Group) before writing the preview. Let me gather recent earnings materials, filings, and news.I'll read the most recent earnings materials and get news/price context.Let me get stock price context, sector/managed care news, and the year-ago Q2 2025 quarter for comparison.Let me get analyst consensus expectations and any recent CI-specific news.# The Cigna Group (CI) — Q2 2026 Earnings Preview
Cigna reports its June-quarter results Thursday morning, and this is a notable one: it will be the first full quarter with Brian Evanko as CEO (he stepped up July 1) and David Cordani in the newly created Executive Chair role. Ann Dennison remains CFO. Expect analysts to probe whether the strategy, capital-allocation framework, and guidance philosophy carry forward unchanged — Evanko has signaled continuity with a few areas of "intensification" (data/AI, lower-cost care, moving upstream into prevention).
Consensus expectations (Street): - Adjusted EPS: ~$7.58–$7.60, up roughly 5–6% YoY from $7.20 in Q2 2025. - Revenue: ~$70–71 billion, up roughly 4.5–6% YoY from $67.2B. - Cigna has beaten the bottom-line consensus in each of the last four quarters, most recently in Q1 2026 ($7.79 actual vs. ~$7.60 expected).
Management's own roadmap for the quarter (given on the Q1 call) is the most important anchor: they guided Q2 adjusted EPS to ~25% of the full-year ≥$30.35 outlook, which pencils out to roughly $7.59 — essentially right on consensus. So the "beat" bar is modest; the debate is really about guidance and medical-cost trend, not the printed number.
This is the single most-watched line, and management has pre-conditioned the Street for a higher Q2 MCR: - Full-year 2026 MCR guidance: 83.7%–84.7% (unchanged after Q1). - Q1 came in at a very strong 79.8% (helped by light flu, weather-related care deferrals, and a favorable bronze-plan mix on the exchanges). - Management explicitly guided Q2 MCR to be slightly ABOVE the high end (i.e., >84.7%), driven by (a) normal seasonality, (b) a steeper seasonal curve this year because the divested Medicare book used to flatten it, and (c) the bronze-heavy individual mix that front-loads margin.
Key point: a Q2 MCR of ~85% is expected and pre-communicated. The market reaction will hinge on whether the underlying trend is merely "elevated but stable" (management's framing — they say cost trend has not accelerated) versus any sign of genuine deterioration. Cigna has less direct exposure to the Medicare Advantage cost problems that have plagued peers, but sentiment is fragile.
Sector read-through is critical this week: Humana reported the day before (7/29) — it beat on EPS but held its ≥$9 full-year outlook unchanged, and the stock fell ~4%, with analysts calling the un-raised guide a "disappointment." That tells you the sector is in a "prove it, then raise it" mood. The relevant question for CI: does it raise the full-year again? After raising to ≥$30.35 in Q1, another raise (or lack of one) will set the tone.
Evernorth Health Services (the growth engine, ~60% of profit) — FY guide: ≥$6.9B pretax. - Specialty & Care Services is the star: pretax earnings +20% YoY in Q1 on strong specialty volumes, biosimilar/specialty-generic adoption (Humira and Stelara $0-out-of-pocket programs, generic Revlimid as supply eases), plus the Shields Health Solutions investment contribution. Watch for continued high-end-of-range growth and any lift in the Shields/CarePathRx contribution. - Pharmacy Benefit Services is the drag investors have accepted: pretax earnings -28% (~$150M) in Q1 on large-client renewals/extensions and investment spend for the new rebate-free "Signature" model. Management flagged that Signature investment spend is weighted to the back half, so the YoY PBS decline should persist. Watch the 2027 selling-season commentary and retention (they targeted mid-90s%+; ended 2026 at 97%+) — that's the tell on whether the model transition is dilutive to the client base.
Cigna Healthcare (~40% of profit) — FY guide: ≥$4.525B pretax, with first-half earnings running slightly above 60% of the full year (i.e., expect a stronger 1H, weaker 2H by design). - Q1 was very strong (+18% YoY pretax) on U.S. Employer and Individual margin. Look for commercial membership/persistency, rate adequacy, and stop-loss commentary. Prior-year reserve development (favorable ~$188M in Q1) is worth monitoring for reserve quality.
At Q1, Cigna announced two proactive moves. Any progress here could move the stock: - Exiting the individual exchange (ACA) business at year-end 2026 — supporting members through 2027 open enrollment. This frees modest capital and removes a small, sub-scale business. (Note: broader ACA subsidy/policy noise is a tailwind risk they're stepping away from.) - Strategic review of eviCore (prior-authorization / utilization management) — could result in a partnership or combination. No transaction was in hand as of April, so any update is possible incremental news.
These fit a long track record of portfolio discipline (group life/disability sale, the March 2025 Medicare/HCSC divestiture). The strategic message: concentrate capital on Specialty & Care, PBS, and the flagship U.S. Employer platform.
CI trades around $296 (7/29 close), up roughly 6% YTD — a middling performer within managed care, having largely avoided the sharp late-January drawdown that hit UNH and ELV. Shares ran to ~$304 in mid-July before pulling back into the print. With the stock mid-range and the Q2 EPS bar effectively pre-set by management's own ~25%-of-FY guide, the swing factor is the full-year guide and MCR trend commentary, not the headline beat.
Bull case into the print: another EPS raise; specialty momentum intact; benign cost-trend language; constructive Signature/2027-selling-season and eviCore updates.
Bear/risk case: Q2 MCR lands above the (already-elevated) guided level with any hint of accelerating trend; guidance merely reaffirmed (Humana-style "disappointment"); PBS drag deepens; or new leadership strikes a more conservative tone.
| Metric | Q2'25 Actual | FY26 Guide / Q2 Framing | Q2'26 Consensus |
|---|---|---|---|
| Adjusted EPS | $7.20 | FY ≥ $30.35; Q2 ≈ 25% of FY (~$7.59) | ~$7.58–$7.60 |
| Total revenue | $67.2B | — | ~$70–71B |
| Cigna Healthcare MCR | 83.2% | FY 83.7–84.7%; Q2 slightly above high end | ~85% |
| Evernorth pretax | $1,696M | FY ≥ $6.9B | Specialty ↑ / PBS ↓ YoY |
| Cigna Healthcare pretax | $1,094M | FY ≥ $4.525B (1H ~60%+) | — |
Bottom line: The number itself should be close to in-line by management's own math. The report is really about (1) whether the full-year outlook gets raised again, (2) the tone on medical-cost trend and the seasonal Q2 MCR step-up, (3) PBS/Signature transition and 2027 retention, and (4) the first strategic signals from the Evanko-led team ahead of September's Investor Day.
Note: This preview is based on Cigna's own disclosures (Q1 2026 and Q2 2025 results/guidance), publicly reported analyst consensus, and current sector news; it is informational and not investment advice.